$NSPR, InspireMD (NASDAQ:NSPR) Earning Favorabl
Post# of 23081
(Total Views: 241)
Posted On: 07/06/2017 10:31:31 AM
$NSPR,
InspireMD (NASDAQ:NSPR) Earning Favorable News Coverage, Study Shows
Posted by Joseph Casey on Jul 6th, 2017 // No Comments
InspireMD logoNews coverage about InspireMD (NASDAQ:NSPR) has trended positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. InspireMD earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near term.
InspireMD (NASDAQ:NSPR) opened at 0.583 on Thursday. The stock’s market cap is $4.33 million. InspireMD has a 12 month low of $0.50 and a 12 month high of $7.50. The stock’s 50 day moving average price is $0.54 and its 200-day moving average price is $1.46.
About InspireMD
InspireMD, Inc is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.
Insider Buying and Selling by Quarter for InspireMD (NASDAQ:NSPR)
Receive News & Ratings for InspireMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.
InspireMD (NASDAQ:NSPR) Earning Favorable News Coverage, Study Shows
Posted by Joseph Casey on Jul 6th, 2017 // No Comments
InspireMD logoNews coverage about InspireMD (NASDAQ:NSPR) has trended positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. InspireMD earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near term.
InspireMD (NASDAQ:NSPR) opened at 0.583 on Thursday. The stock’s market cap is $4.33 million. InspireMD has a 12 month low of $0.50 and a 12 month high of $7.50. The stock’s 50 day moving average price is $0.54 and its 200-day moving average price is $1.46.
About InspireMD
InspireMD, Inc is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.
Insider Buying and Selling by Quarter for InspireMD (NASDAQ:NSPR)
Receive News & Ratings for InspireMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.
(2)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'